Unlocking the potential of
genomic medicine

2018 News Releases

Date Title
Toggle Summary09/03/2015
PHILADELPHIA , Sept. 3, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan
Toggle Summary08/10/2015
Initiated enrollment in peritoneal dialysis study in U.S. Awarded $3.4 million grant from the Israeli Office of the Chief Scientist Advanced collaboration activities with CHOP PHILADELPHIA , Aug. 10, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) (the Company), the developer of a proprietary
Toggle Summary07/15/2015
PHILADELPHIA , July 15, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan
Toggle Summary06/29/2015
PHILADELPHIA , June 29, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan
Toggle Summary06/17/2015
PHILADELPHIA , June 17, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan
Toggle Summary06/11/2015
PHILADELPHIA , June 11, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan
Toggle Summary06/10/2015
PHILADELPHIA , June 10, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan
Toggle Summary06/04/2015
- New Data Presented from Ongoing Phase 1/2 Study of TARGT EPO TM PHILADELPHIA , June 4, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene
Toggle Summary05/07/2015
PHILADELPHIA , May 7, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan
Toggle Summary04/17/2015
Commenced enrollment in mid-dose arm of MDGN-201 study Initiated peritoneal dialysis study in Israel Filed U.S. IND for TARGT EPO renal anemia programs Advanced collaboration activities with CHOP Progressed TARGT CNS program with Harvard University PHILADELPHIA , April 17, 2015 (GLOBE NEWSWIRE) --